secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001493152-23-009849
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Bioscience prelim Q4 revenue $270-280K, up 15-19% QoQ; signs Wisconsin clinic acquisition
--------------------------------------------------------------------------------

- Q4 2022 revenue expected $270K-$280K, up 15-19% from Q3 2022's $235K.
- Full year 2022 revenue expected $815K-$825K, up 38-40% YoY excluding $3.6M deferred revenue from Ferring.
- Gross operating expenses for FY2022 expected $10.5M-$11.0M, up 14-19% YoY.
- Signed binding purchase agreement for Wisconsin Fertility Institute (clinic generated ~$5.5M revenue, $1.9M net income in trailing 12 months).
- Closed registered direct offering for ~$3M gross proceeds in March 2023; 10-K filing extended to April 15, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315223009849/0001493152-23-009849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315223009849/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-009849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer